Humacyte (NASDAQ:HUMAW – Get Free Report) is projected to post its results before the market opens on Monday, August 17th. Analysts expect the company to announce earnings of ($0.0980) per share and revenue of $1.1190 million for the quarter.

HUMAW stock opened at $0.01 on Monday. Humacyte has a 1-year low of $0.00 and a 1-year high of $0.50. The business’s 50 day simple moving average is $0.02 and its 200 day simple moving average is $0.07.

(Get Free Report)

Humacyte, Inc (NASDAQ:HUMAW) is a clinical-stage biotechnology company specializing in the development and manufacture of human acellular vessels (HAVs). These off-the-shelf, bioengineered vascular conduits are designed to serve as living implants for patients requiring vascular access, including those undergoing hemodialysis, as well as for peripheral artery disease and vascular trauma. Humacyte’s proprietary tissue-engineering platform leverages human vascular cells cultured on biodegradable scaffolds, which are subsequently decellularized to produce durable, non-immunogenic vessels that support natural tissue regeneration.

Founded in 2007 and headquartered in Durham, North Carolina, Humacyte has advanced its lead candidate, the HAV, through multiple clinical trials in the United States and Europe.

• Five stocks we like better than Humacyte
• Albemarle’s Blowout Quarter Shows Why Lithium Still Matters
• Can DICK’S Turn Foot Locker Into a Winner?
• Why Dutch Bros Plunged Despite a Q2 Earnings Beat and Record Revenue
• Take-Two’s Q1 Results Leave GTA 6 Bulls Stuck in the Fog of War

Receive News & Ratings for Humacyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humacyte and related companies with MarketBeat.com's FREE daily email newsletter.